BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bernatova I, Liskova S. Mechanisms Modified by (-)-Epicatechin and Taxifolin Relevant for the Treatment of Hypertension and Viral Infection: Knowledge from Preclinical Studies. Antioxidants (Basel) 2021;10:467. [PMID: 33809620 DOI: 10.3390/antiox10030467] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Das A, Baidya R, Chakraborty T, Samanta AK, Roy S. Pharmacological basis and new insights of taxifolin: A comprehensive review. Biomed Pharmacother 2021;142:112004. [PMID: 34388527 DOI: 10.1016/j.biopha.2021.112004] [Reference Citation Analysis]
2 Hid EJ, Mosele JI, Prince PD, Fraga CG, Galleano M. ( -)-Epicatechin and cardiometabolic risk factors: a focus on potential mechanisms of action. Pflugers Arch 2021. [PMID: 34812946 DOI: 10.1007/s00424-021-02640-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Al-Shuhaib MBS, Hashim HO, Al-Shuhaib JMB. Epicatechin is a promising novel inhibitor of SARS-CoV-2 entry by disrupting interactions between angiotensin-converting enzyme type 2 and the viral receptor binding domain: A computational/simulation study. Comput Biol Med 2021;141:105155. [PMID: 34942397 DOI: 10.1016/j.compbiomed.2021.105155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ferenczyová K, Kindernay L, Vlkovičová J, Kaločayová B, Rajtík T, Barteková M. Pharmacology of Catechins in Ischemia-Reperfusion Injury of the Heart. Antioxidants (Basel) 2021;10:1390. [PMID: 34573022 DOI: 10.3390/antiox10091390] [Reference Citation Analysis]
5 Kreiser T, Zaguri D, Sachdeva S, Zamostiano R, Mograbi J, Segal D, Bacharach E, Gazit E. Inhibition of Respiratory RNA Viruses by a Composition of Ionophoric Polyphenols with Metal Ions. Pharmaceuticals 2022;15:377. [DOI: 10.3390/ph15030377] [Reference Citation Analysis]